NEJM Pre-Submission Checklist: Is Your Paper Ready for the World's Most Cited Medical Journal?

4. Is the study design strong enough for the claims?

NEJM strongly favors large randomized controlled trials. Observational studies are published but face higher scrutiny. Post-hoc analyses of trials designed to answer different questions are typically desk rejected. The design must be pre-specified and appropriate for the primary outcome.

5. Is the trial registered before enrollment began?

NEJM requires prospective trial registration in an approved registry (ClinicalTrials.gov, WHO ICTRP) before the first participant is enrolled. Manuscripts describing unregistered trials are returned without review. The registration number must appear in the abstract.

6. Does the registered primary outcome match the manuscript?

Editors check. If the primary outcome in the published paper differs from the registered primary outcome, this raises selective reporting concerns. Any protocol amendments must be documented and justified.

7. Will the analysis survive independent statistical review?

NEJM sends papers that advance to revision for independent statistical review by one of five statistical consultants. This review is rigorous and evaluates sample size justification, analytical methods, missing data handling, multiplicity corrections, and subgroup analysis validity. Many authors are not prepared for this level of statistical scrutiny.

Prepare by ensuring: sample size is justified with a power analysis, the primary analysis is pre-specified, sensitivity analyses address missing data, subgroup analyses are identified as pre-specified or exploratory, and confidence intervals are reported alongside p-values.

8. Are the results reported with appropriate precision?

Exact p-values (not just "p<0.05"). Confidence intervals for all primary outcomes. Effect sizes, not just significance. Hazard ratios, odds ratios, or absolute risk differences as appropriate. NEJM has strict statistical reporting standards.

9. Are all ethics approvals documented?

A statement, where applicable, that the research protocol was approved by the relevant institutional review boards or ethics committees and that all human participants gave written informed consent. DSMB (Data Safety Monitoring Board) oversight described if applicable.

10. Have all authors declared conflicts and confirmed authorship?

NEJM permits only one corresponding author. Credit for authorship requires substantial contributions to conception, design, data acquisition, analysis, or interpretation. All conflicts of interest must be declared. NEJM has detailed financial disclosure requirements.

11. Is AI use disclosed?

NEJM requires you to disclose at submission whether AI-assisted technologies (such as large language models, chatbots, or image creators) were used to produce the submitted work, with a description in both the cover letter and the submitted work. If you used ChatGPT, Claude, or any AI tool, disclose it.

12. Have you considered a Rapid Review request?

NEJM offers Rapid Review for time-sensitive findings. NEJM says Rapid Review requests are most often approved for studies that deal with urgent public health concerns, have potential to dramatically change clinical practice or to affect mortality, or are timed to imminent meeting presentations. NEJM generally replies to the request within three business days, and an initial decision on publication is typically reached within two weeks. Approval does not guarantee acceptance or expedited publication.

For non-urgent submissions, consider whether a presubmission inquiry (a short form describing the work, which an NEJM editor generally answers by email within one week) would help calibrate expectations before investing in the full submission.

For any randomized trial, NEJM asks for a flow diagram in CONSORT format and encourages authors to submit the relevant information from the CONSORT checklist, in the manuscript or a supplementary appendix. Observational studies and systematic reviews are commonly reported against STROBE and PRISMA; NEJM's pages do not name those checklists, but they do require a statistical analysis plan with observational studies, and NEJM's review takes the methods in the protocol and analysis plan into account.

Attach the completed checklist with page and line numbers rather than leaving the items for a reviewer to reconstruct. This page was last reviewed October 8, 2026 against the NEJM editorial policies.

NEJM says fewer than 5% of research reports it receives are eventually published. NEJM submission readiness check. The Manusights free scan evaluates your manuscript against NEJM's editorial standards in about two to three minutes.

For a paper targeting NEJM, the stakes are the highest in academic medicine. The NEJM submission readiness check provides citation-integrity checks against scholarly metadata sources, figure-level feedback, and journal-specific calibration. If the trial or cohort is the centerpiece of a career, the Submission-Ready Dossier ($99) adds a simulated multi-reviewer critique of the design and endpoints, the objections a statistical reviewer is likely to raise, and a fallback plan in case NEJM passes.

The Executive Editor reviews every research submission personally. The desk decision is based on:

• Clinical impact too narrow. The finding matters within one specialty but does not change broad clinical practice.

• Study design limitations. An observational study making causal claims. A post-hoc analysis of a different trial. An underpowered study with borderline results.

• The result is confirmatory. Confirming what is already known, even with a larger trial, is less interesting than a finding that changes practice.

• Registration problems. Unregistered trials are returned immediately. Registration after enrollment began is flagged.

• The paper has been substantially published. NEJM will not consider a manuscript that has been published elsewhere or whose primary results have been released, except for activities such as presenting at scientific meetings or posting on a nonprofit preprint server. Notify NEJM of any preprint.

If your paper survives the Executive Editor's first review (NEJM says about 10% of submissions are declined at that stage), here's the process:

1. External review. An associate editor decides whether the paper meets criteria for quality, novelty, and potential clinical impact, and then sends it to at least two peer reviewers. In almost all cases, two peer reviewers evaluate each submission within one to two weeks.

1. Statistical review (after Revision status). If a manuscript is moved to Revision status, it is sent for statistical review. Most research manuscripts published by NEJM undergo at least one statistical review by one of five statistical consultants. Most journals rely on reviewers to catch statistical issues.

1. Editorial conference. Associate editors bring papers to a weekly editorial meeting attended by all deputy editors, associate editors, and statistical consultants. A decision to decline must be seconded by a deputy editor.

1. First decision letter. The paper is assigned one of three statuses: rejection, provisional rejection (not suitable unless the authors conduct further research or collect additional data), or revision.

1. Revision. NEJM publishes no standard revision window. The associate editor again reviews the revised paper and decides whether further peer or statistical review is needed, and multiple iterations are likely. NEJM requires two versions of each revision, one with changes tracked or highlighted and one without.

NEJM publishes no total timeline from submission to acceptance.

For manuscripts targeting NEJM, the biggest issue is usually not formatting; it is whether the paper already reads like a general-medicine paper in the title, the abstract, and the first figure. We usually see authors underestimate how much the journal cares about immediate clinical consequence and overestimate how much the Executive Editor will infer from a technically strong but narrowly framed abstract. Three patterns recur often enough that we check each one before submission:

• Specialty framing on a general-medicine target: the abstract and introduction frame the advance for one specialty, so the Executive Editor cannot see why physicians across fields would change practice. The fix is in the framing, not the data.

• Statistics not ready for the independent consultant: the sample-size justification, the multiplicity correction, the missing-data handling, or the pre-specified analysis plan is incomplete, and NEJM's independent statistical consultants will find it.

• Registry-to-manuscript mismatch: the registered primary outcome, the protocol, and the manuscript's primary outcome do not align cleanly, which reads as selective reporting at a journal that checks the registry against the paper.

We trace each pattern back to a specific part of the manuscript, the title, the abstract, the methods, the statistics, or the trial-registration record, so the fix is a framing or reporting decision rather than a rewrite of the science.

The cheapest version of this check is the one done before submission: read only the title and the first three sentences of the abstract and ask whether a physician outside the specialty would change practice on that alone. If the answer is no, the package is not yet ready for the Executive Editor's two-minute read, regardless of how strong the underlying trial is.

If the practice implication is not obvious on page one, the rest of the package rarely matters, because the desk decision is made in the first read. Your manuscript is never used to train any model when we run it, and every flag is tied to a passage in your own text.

Worth the investment if:

• You are targeting NEJM where desk rejection is high

• A rejection would cost 3-6 months in resubmission cycles

• The paper is career-critical

• You want an independent assessment before submission

Skip it if:

• You have a strong track record at NEJM and know the editors

• Experienced colleagues have already reviewed the manuscript thoroughly

• Your timeline is too tight to act on the feedback

• The study has fundamental design issues needing new experiments